Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 3, 2007, Pages 341-344

  Sader, Helio S ^a,b   Hsiung, Andre ^c   Fritsche, Thomas R ^a   Jones, Ronald N ^a,d  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hardy Diagnostics   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cefepime; ESBL; Escherichia coli; Klebsiella; Piperacillin tazobactam

Indexed keywords

AZTREONAM; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANALYTICAL ERROR; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; ESCHERICHIA COLI; KLEBSIELLA; NONHUMAN; NORTH AMERICA; PHENOTYPE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN;

EID: 33847293756     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.08.016     Document Type: Article

References (14)

1. Bhavnani S.M., Ambrose P.G., Craig W.A., Dudley M.N., and Jones R.N. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 54 (2006) 231-236
2. Bratu S., Mooty M., Nichani S., Landman D., Gullans C., Pettinato B., Karumudi U., Tolaney P., and Quale J. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49 (2005) 3018-3020
3. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 7th ed. (2006), CLSI, Wayne, PA (Approved Standards M7-A7)
4. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 16th Informational Supplement M100-S16 (2006), CLSI, Wayne, PA
5. Deshpande L.M., Jones R.N., Fritsche T.R., and Sader H.S. Occurrence and characterization of carbapenemases produced by Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb. Drug Resist. (2006) (In press)
6. Deshpande L.M., Jones R.N., Fritsche T.R., and Sader H.S. Occurrence of plasmidic Amp-C type β-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). Int. J. Antimicrob. Agents (2006) (In press)
7. Jones R.N., Biedenbach D.J., and Gales A.C. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY Antimicrobial Surveillance Program (USA, 1997-2000). Int. J. Antimicrob. Agents 21 (2003) 1-7
8. Jones R.N., Craig W.A., Ambrose P.G., Dudley M.N., and Pottumarthy S. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 β-lactams: adjustments of breakpoints for strains producing extended spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. 52 (2005) 235-246
9. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., Oh M.D., and Choe K.W. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. 48 (2004) 4574-4581
10. Maglio D., Ong C., Banevicius M.A., Geng Q., Nightingale C.H., and Nicolau D.P. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-β-lactamase-producing Escherichia coli at various inocula. Antimicrob. Agents Chemother. 48 (2004) 1941-1947
11. Paterson D.L., Ko W.C., Von Gottberg A., Casellas J.M., Mulazimoglu L., Klugman K.P., Bonomo R.A., Rice L.B., McCormack J.G., and Yu V.L. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39 (2001) 2206-2212
12. Paterson D.L., Hujer K.M., Hujer A.M., Yeiser B., Bonomo M.D., Rice L.B., and Bonomo R.A. Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob. Agents Chemother. 47 (2003) 3554-3560
13. Philippon A., Arlet G., and Jacoby G.A. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46 (2002) 1-11
14. Pottumarthy S., Deshpande L.M., Sader H.S., and Jones R.N. Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum β-lactamase-producing organisms. Diagn. Microbiol. Infect. Dis. 52 (2005) 95-99